NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: GUFICBIO · data 2026-11-01
Gufic Biosciences Limited
In plain words
Price: 11.6% below its 52-week high of ₹467.8.
Delivery: 53.1% of traded shares were kept for delivery over the last 10 sessions, against 51.9% over the last 60.
Latest results: a net profit of ₹22 cr for the quarter ended Jun 2026 (+70.7% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹981 cr |
| Net profit (last 12 months) | ₹73 cr |
| Sales growth, 3 years (yearly) | 11.0% |
| Profit growth, 3 years (yearly) | -6.9% |
At a glance
Promoters 72.5% (unchanged in a year), pledged 0.0%, institutions 3.8%.
P/E 56.5, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 10.1%, ROCE 15.3%, operating margin 13.6%: how much profit it earns on the money it uses.
Debt/equity 0.61, Profit growth -6.9% and sales growth 11.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Profit fell 6.9% a year over 3 years.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
GUFICBIO Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹260.82 crore, up 16.6% YoY and up 3.6% QoQ.
Net profit was ₹22.31 crore, up 70.7% YoY and up 1.9% QoQ.
Operating margin was 17.9% (14.9% a year ago).
EPS was ₹2.22, up 70.8% YoY and up 1.8% QoQ.
GUFICBIO के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹260.82 करोड़; पिछले साल की तुलना में 16.6% की बढ़त, पिछली तिमाही की तुलना में 3.6% की बढ़त।
शुद्ध मुनाफ़ा: ₹22.31 करोड़; पिछले साल की तुलना में 70.7% की बढ़त, पिछली तिमाही की तुलना में 1.9% की बढ़त।
ऑपरेटिंग मार्जिन: 17.9% (एक साल पहले 14.9%)।
EPS: ₹2.22; पिछले साल की तुलना में 70.8% की बढ़त, पिछली तिमाही की तुलना में 1.8% की बढ़त।
GUFICBIOના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹260.82 કરોડ; ગયા વર્ષની સરખામણીએ 16.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 3.6% વધારો.
ચોખ્ખો નફો: ₹22.31 કરોડ; ગયા વર્ષની સરખામણીએ 70.7% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 1.9% વધારો.
ઓપરેટિંગ માર્જિન: 17.9% (એક વર્ષ પહેલાં 14.9%).
EPS: ₹2.22; ગયા વર્ષની સરખામણીએ 70.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 1.8% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
16/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 8/30: Delivery 51.0% over the last 20 sessions vs 47.4% in the 40 before (1.08x); shares delivered per day 0.84x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 3/15: 1 scheme hold it, about ₹17 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 28 Aug 26Dividend Dividend ₹0.1 (ex-date) +1.0% next session
- 14 Aug 26Results Q1 FY27 results: profit +70.7% YoY -2.8% next session
- 29 May 26Results Q4 FY26 results: profit +183.7% YoY +6.4% next session
- 13 Feb 26Results Q3 FY26 results: profit −35.7% YoY -6.3% next session
- 14 Nov 25Results Q2 FY26 results: profit −22.7% YoY -3.5% next session
- 22 Sept 25Dividend Dividend ₹0.1 (ex-date) +0.4% next session
- 13 Aug 25Results Q1 FY26 results: profit −37.3% YoY +0.5% next session
- 30 May 25Results Q4 FY25 results: profit −61.5% YoY -6.3% next session
- 14 Feb 25Results Q3 FY25 results: profit −13.3% YoY -0.7% next session
- 15 Nov 24Results Q2 FY25 results: profit −6.2% YoY -8.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹261 cr | ₹22 cr | +70.7% | 17.9% | 2.22 |
| Mar 2026 | ₹252 cr | ₹22 cr | +183.7% | 18.7% | 2.18 |
| Dec 2025 | ₹231 cr | ₹12 cr | -35.7% | 14.3% | 1.24 |
| Sept 2025 | ₹237 cr | ₹17 cr | -22.7% | 16.0% | 1.68 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 72.50% | 72.50% | 72.50% | 72.50% |
| Foreign institutions (FII) | 0.45% | 0.46% | 0.42% | 0.44% |
| Domestic institutions (DII) | 3.38% | 3.68% | 3.83% | 3.74% |
| Mutual funds | 3.03% | 3.43% | 3.63% | 3.53% |
| Retail investors | 11.72% | 11.41% | 11.30% | 11.52% |
| Number of shareholders | 29,726 | 29,753 | 29,223 | 30,362 |
Common questions
What was Gufic Biosciences Limited's latest quarterly profit?
Gufic Biosciences Limited reported a net profit of ₹22 cr for the quarter ended Jun 2026 (+70.7% on the same quarter a year earlier), on revenue of ₹261 cr.
How much do promoters hold in Gufic Biosciences Limited?
Promoters held 72.50% of Gufic Biosciences Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Gufic Biosciences Limited debt-free?
Its latest reported debt-to-equity ratio is 0.61.
What is Gufic Biosciences Limited's P/E ratio?
About 56.5, based on the last 12 months' earnings and a price of ₹413.55 (data 2026-11-01).
What is the 52-week high and low of Gufic Biosciences Limited?
The 52-week high is ₹467.8 and the 52-week low is ₹268.
Mutual funds holding Gufic Biosciences Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 1 scheme holding about ₹17 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 0.29% | ₹17 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Gufic Biosciences Limited | ₹413.55 | ₹4,134 cr | 56.5 | — | 10.1% | 15.3% | 0.61 | +23.7% |
| Gujarat Themis Biosyn Ltd | ₹363.2 | ₹4,718 cr | 81.3 | — | 17.4% | 18.2% | 0.56 | -21.9% |
| RPG Life Sciences Limited | ₹2,575.7 | ₹4,255 cr | 35.6 | — | 20.3% | 21.3% | 0.03 | +5.3% |
| Evonile Pharma Limited | ₹1,692.4 | ₹4,182 cr | 42.7 | — | 11.6% | 11.8% | 0 | +144.9% |
| Zota Health Care Ltd. | ₹1,328.8 | ₹4,031 cr | — | 7.4 | -16.1% | -9.7% | 0.39 | -15.4% |
| Aarti Drugs Limited | ₹435.2 | ₹3,977 cr | 20.8 | — | 13.4% | 13.2% | 0.37 | -12.1% |
Compare GUFICBIO with GUJTHEM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GUFICBIO in NSE Scanner →